Aytu BioPharma (NASDAQ:AYTU)报告Q损失0.82美元/share(误差0.37美元),收入17.98M美元-14美元。 Aytu BioPharma (NASDAQ: AYTU) reported a Q loss of $0.82/share ($0.37 miss), $17.98M revenue, -14.

Aytu BioPharma (NASDAQ:AYTU)报告季度损失每股0.82美元,损失估计数为0.37美元。 Aytu BioPharma (NASDAQ: AYTU) reported a quarterly loss of $0.82 per share, missing estimates by $0.37. 该公司赚取收入1 798万美元,净负差14.60%,股本收益31.31%。 The company earned $17.98 million in revenue, with a negative net margin of 14.60% and a return on equity of -31.31%. 继该报告之后,股票降至2.36美元,市场上限为1 409万美元。 Following the report, shares fell to $2.36, and the market cap stands at $14.09 million. Aytu生物制药公司专门从事新型治疗和消费者保健产品,包括ADDHD的治疗。 Aytu BioPharma specializes in novel therapeutics and consumer healthcare products, including treatments for ADHD.